 James Maloney
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cricoid Cartilage | 1 | 2023 | 17 | 0.830 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2016 | 528 | 0.820 |
Why?
| | Bronchoscopy | 2 | 2023 | 216 | 0.820 |
Why?
| | Pulmonary Eosinophilia | 1 | 2021 | 27 | 0.710 |
Why?
| | Vaping | 1 | 2021 | 54 | 0.660 |
Why?
| | Lung Injury | 1 | 2021 | 211 | 0.580 |
Why?
| | Marijuana Smoking | 1 | 2021 | 247 | 0.560 |
Why?
| | Apyrase | 1 | 2017 | 16 | 0.550 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2020 | 158 | 0.520 |
Why?
| | Serum | 1 | 2016 | 58 | 0.510 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 284 | 0.490 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2023 | 2062 | 0.480 |
Why?
| | Plasma | 1 | 2016 | 206 | 0.460 |
Why?
| | Antigens, CD | 1 | 2017 | 487 | 0.450 |
Why?
| | Acute Lung Injury | 4 | 2020 | 280 | 0.450 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 287 | 0.410 |
Why?
| | Blood Platelets | 1 | 2016 | 386 | 0.400 |
Why?
| | Pulmonary Alveoli | 1 | 2015 | 403 | 0.400 |
Why?
| | Hypertension, Pulmonary | 4 | 2020 | 1894 | 0.400 |
Why?
| | Endothelial Cells | 2 | 2015 | 749 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 5 | 2017 | 2271 | 0.380 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.380 |
Why?
| | Sepsis | 7 | 2023 | 576 | 0.350 |
Why?
| | Cytokines | 3 | 2023 | 2022 | 0.340 |
Why?
| | Mutation, Missense | 1 | 2011 | 316 | 0.330 |
Why?
| | Scopolamine Derivatives | 1 | 2009 | 7 | 0.320 |
Why?
| | Thrombospondin 1 | 2 | 2020 | 26 | 0.310 |
Why?
| | Cholinergic Antagonists | 1 | 2009 | 29 | 0.310 |
Why?
| | Lung | 2 | 2021 | 3937 | 0.300 |
Why?
| | Transforming Growth Factor beta | 3 | 2017 | 462 | 0.290 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2007 | 43 | 0.280 |
Why?
| | Cystic Fibrosis | 1 | 2016 | 1066 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2023 | 1204 | 0.260 |
Why?
| | Pneumonia, Aspiration | 2 | 2002 | 18 | 0.250 |
Why?
| | Inhalation | 2 | 2002 | 28 | 0.250 |
Why?
| | Thrombospondins | 1 | 2004 | 7 | 0.230 |
Why?
| | Expressed Sequence Tags | 1 | 2004 | 40 | 0.230 |
Why?
| | Forms and Records Control | 1 | 2004 | 22 | 0.230 |
Why?
| | Databases, Nucleic Acid | 1 | 2004 | 33 | 0.220 |
Why?
| | Hypoxia | 3 | 2020 | 1085 | 0.220 |
Why?
| | Enteral Nutrition | 2 | 2002 | 186 | 0.220 |
Why?
| | Altitude Sickness | 1 | 2005 | 141 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2009 | 1000 | 0.210 |
Why?
| | Surgical Instruments | 1 | 2023 | 51 | 0.200 |
Why?
| | Peripheral Tolerance | 1 | 2022 | 15 | 0.190 |
Why?
| | Biopsy | 2 | 2021 | 1087 | 0.190 |
Why?
| | Hirudins | 1 | 2002 | 53 | 0.190 |
Why?
| | Humans | 29 | 2023 | 129687 | 0.190 |
Why?
| | Cadaver | 1 | 2023 | 308 | 0.190 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1433 | 0.180 |
Why?
| | Point-of-Care Systems | 1 | 2002 | 148 | 0.180 |
Why?
| | Heparin | 1 | 2002 | 254 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2002 | 189 | 0.170 |
Why?
| | Interleukin-6 | 3 | 2023 | 724 | 0.170 |
Why?
| | Symptom Assessment | 1 | 2021 | 125 | 0.160 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 107 | 0.160 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2021 | 89 | 0.160 |
Why?
| | Vasoconstriction | 1 | 2020 | 199 | 0.160 |
Why?
| | Antihypertensive Agents | 1 | 2003 | 485 | 0.160 |
Why?
| | Lung Diseases | 1 | 2005 | 741 | 0.150 |
Why?
| | Arthritis, Rheumatoid | 1 | 2007 | 1098 | 0.150 |
Why?
| | Anticoagulants | 1 | 2002 | 637 | 0.140 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.140 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2008 | 0.130 |
Why?
| | Myosin-Light-Chain Kinase | 2 | 2007 | 20 | 0.130 |
Why?
| | Genotype | 2 | 2023 | 1829 | 0.130 |
Why?
| | Curriculum | 1 | 2023 | 925 | 0.130 |
Why?
| | Platelet Count | 1 | 2016 | 82 | 0.130 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 302 | 0.130 |
Why?
| | Female | 14 | 2021 | 68751 | 0.130 |
Why?
| | Platelet Aggregation | 1 | 2016 | 97 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 216 | 0.120 |
Why?
| | Introns | 3 | 2011 | 249 | 0.120 |
Why?
| | HEK293 Cells | 1 | 2017 | 697 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2015 | 264 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2004 | 1644 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 462 | 0.110 |
Why?
| | Adult | 8 | 2021 | 35607 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2016 | 3381 | 0.110 |
Why?
| | Models, Biological | 1 | 2020 | 1724 | 0.100 |
Why?
| | Macrophages | 1 | 2020 | 1489 | 0.100 |
Why?
| | Cell Line | 2 | 2015 | 2779 | 0.100 |
Why?
| | Asthma | 2 | 2021 | 2225 | 0.100 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 24 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2011 | 51 | 0.090 |
Why?
| | Interleukin-1 | 1 | 2015 | 956 | 0.090 |
Why?
| | Conserved Sequence | 1 | 2011 | 227 | 0.090 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 199 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 636 | 0.090 |
Why?
| | Haplotypes | 3 | 2007 | 474 | 0.080 |
Why?
| | RNA Splicing | 1 | 2011 | 259 | 0.080 |
Why?
| | Middle Aged | 9 | 2017 | 31165 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 259 | 0.080 |
Why?
| | Respiration, Artificial | 2 | 2011 | 614 | 0.080 |
Why?
| | Tiotropium Bromide | 1 | 2009 | 19 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 399 | 0.080 |
Why?
| | Male | 10 | 2017 | 63691 | 0.080 |
Why?
| | Toll-Like Receptor 1 | 1 | 2008 | 12 | 0.080 |
Why?
| | Binding Sites | 1 | 2011 | 1251 | 0.070 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2007 | 10 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2007 | 68 | 0.070 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 235 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2009 | 149 | 0.070 |
Why?
| | B-Lymphocytes | 2 | 2022 | 816 | 0.070 |
Why?
| | Risk Factors | 4 | 2009 | 9787 | 0.070 |
Why?
| | Atmospheric Pressure | 1 | 2005 | 23 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2122 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1097 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2006 | 257 | 0.060 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 1326 | 0.060 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 218 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 711 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1441 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2011 | 4102 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1645 | 0.050 |
Why?
| | Multigene Family | 1 | 2004 | 195 | 0.050 |
Why?
| | Xanthine Dehydrogenase | 1 | 2023 | 25 | 0.050 |
Why?
| | Uterus | 1 | 2004 | 207 | 0.050 |
Why?
| | Sildenafil Citrate | 1 | 2003 | 59 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 443 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | Immunoglobulin D | 1 | 2022 | 29 | 0.050 |
Why?
| | Hirudin Therapy | 1 | 2002 | 2 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2008 | 804 | 0.050 |
Why?
| | Sulfones | 1 | 2003 | 108 | 0.050 |
Why?
| | Epoprostenol | 1 | 2003 | 136 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 666 | 0.050 |
Why?
| | Purines | 1 | 2003 | 172 | 0.050 |
Why?
| | Adaptation, Physiological | 1 | 2005 | 521 | 0.050 |
Why?
| | Cohort Studies | 1 | 2011 | 5434 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 5468 | 0.050 |
Why?
| | Inflammation | 2 | 2022 | 2748 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2002 | 287 | 0.040 |
Why?
| | Interferons | 1 | 2022 | 189 | 0.040 |
Why?
| | Vasodilator Agents | 1 | 2003 | 326 | 0.040 |
Why?
| | Antibody Formation | 1 | 2002 | 291 | 0.040 |
Why?
| | Parabiosis | 1 | 2020 | 11 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 47 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 77 | 0.040 |
Why?
| | Piperazines | 1 | 2003 | 339 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 49 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 58 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2020 | 120 | 0.040 |
Why?
| | rho-Associated Kinases | 1 | 2020 | 87 | 0.040 |
Why?
| | Echocardiography | 1 | 2003 | 635 | 0.040 |
Why?
| | Animals | 5 | 2020 | 35404 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 620 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 520 | 0.040 |
Why?
| | Sulfonamides | 1 | 2003 | 497 | 0.040 |
Why?
| | Gene Expression | 1 | 2004 | 1465 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1310 | 0.040 |
Why?
| | Biomarkers | 2 | 2007 | 3969 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2003 | 1005 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 602 | 0.040 |
Why?
| | Antigens, Ly | 1 | 2017 | 44 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 482 | 0.030 |
Why?
| | Critical Illness | 1 | 2002 | 759 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 171 | 0.030 |
Why?
| | Heart Failure | 1 | 2009 | 2147 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4935 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2009 | 10221 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 718 | 0.030 |
Why?
| | Exons | 2 | 2006 | 341 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1468 | 0.030 |
Why?
| | Cattle | 1 | 2017 | 978 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4076 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 553 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2888 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1736 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2007 | 646 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1496 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2489 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 65 | 0.020 |
Why?
| | Pedigree | 1 | 2012 | 483 | 0.020 |
Why?
| | Body Height | 1 | 2011 | 192 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 421 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 515 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2702 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1021 | 0.020 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2008 | 45 | 0.020 |
Why?
| | Prospective Studies | 2 | 2011 | 7145 | 0.020 |
Why?
| | Caribbean Region | 1 | 2007 | 25 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 1988 | 0.020 |
Why?
| | Thymine | 1 | 2006 | 14 | 0.020 |
Why?
| | Cytosine | 1 | 2006 | 48 | 0.020 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 27 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2006 | 92 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1973 | 0.020 |
Why?
| | Homozygote | 1 | 2006 | 195 | 0.020 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2004 | 7 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2006 | 393 | 0.010 |
Why?
| | Cause of Death | 1 | 2006 | 395 | 0.010 |
Why?
| | Shock, Septic | 1 | 2006 | 209 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 385 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 716 | 0.010 |
Why?
| | Risk | 1 | 2006 | 855 | 0.010 |
Why?
| | Reference Values | 1 | 2004 | 796 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2006 | 590 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 505 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 756 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2545 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 872 | 0.010 |
Why?
| | North America | 1 | 2002 | 292 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1033 | 0.010 |
Why?
| | Neutrophils | 1 | 2006 | 1209 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1416 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2004 | 1950 | 0.010 |
Why?
| | Mice | 2 | 2007 | 16982 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1686 | 0.010 |
Why?
| | Aged | 2 | 2007 | 22101 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 20415 | 0.010 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|